Gentium SpA Receives “Hold” Rating from Zacks (GENT)
Gentium SpA (NASDAQ:GENT)‘s stock had its “hold” rating reaffirmed by Zacks in a note issued to investors on Monday, American Banking News reports. They currently have a $23.00 target price on the stock. Zacks‘ target price would suggest a potential downside of 19.38% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Brean Capital raised their price target on shares of Gentium SpA from $24.00 to $38.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at Wedbush raised their price target on shares of Gentium SpA from $20.00 to $35.00 in a research note to investors on Monday, September 30th. They now have an “outperform” rating on the stock.
Shares of Gentium SpA (NASDAQ:GENT) traded down 0.45% during mid-day trading on Monday, hitting $28.53. 53,449 shares of the company’s stock traded hands. Gentium SpA has a 52 week low of $6.96 and a 52 week high of $29.02. The stock’s 50-day moving average is $21.77 and its 200-day moving average is $12.41. The company has a market cap of $432.9 million and a P/E ratio of 98.15.
Gentium SpA (NASDAQ:GENT) last posted its quarterly earnings results on Tuesday, August 13th. The company reported $0.16 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.02 by $0.14.
Gentium S.p.A. is a biopharmaceutical company focused on the development and manufacture of defibrotide, a drug based on single-stranded deoxyribonucleic acid (NASDAQ:GENT) derived from pig intestines.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.